{"product_id":"edgewisetx-business-model-canvas","title":"Edgewise Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise Therapeutics: A Business Model Canvas View of Patient-Focused Muscle Disorder Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Edgewise Therapeutics frames its value proposition around orally available small-molecule therapies, targeted partnerships, and a disciplined R\u0026amp;D model in this Business Model Canvas preview-offering a clear view of its strategy for DMD and BMD and the market opportunity it aims to capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise contracts specialized CROs to run complex, multi‑site trials for its lead candidates, outsourcing patient recruitment, data capture, and monitoring to meet FDA and EMA standards; in 2025 the biotech sector outsourced ~60% of late‑stage trial activity, cutting upfront fixed trial costs by an estimated 30-50% versus in‑house builds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with groups like Parent Project Muscular Dystrophy and Muscular Dystrophy Association give Edgewise direct patient insight and help enroll trials-PPMD reported engaging 50,000+ families in 2024 and MDA supported \u0026gt;15,000 clinical contacts in 2024. These partnerships speed recruitment, improve protocol design for rare-disease needs, and build trust across a community that often faces multi-year diagnostic and access delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics partners with top academic centers-including partnerships begun 2023-2025 with Johns Hopkins and UC San Diego-funding $4.2M in university-led muscle-physiology studies that produced 2 validated neuromuscular targets and 1 IND-enabling lead; these ties drive early discovery, reduce preclinical costs, and keep a steady pipeline of small-molecule therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise uses contract manufacturing organizations (CMOs) to produce active pharmaceutical ingredients and finished oral dosages for clinical trials, ensuring Good Manufacturing Practice (GMP) compliance as it advances toward commercialization; in 2025 the company outsources \u0026gt;90% of manufacturing spend to CMOs to stay capital-light.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified CMOs produce API and tablets\u003c\/li\u003e\n\u003cli\u003eOutsourcing keeps fixed manufacturing capex low\u003c\/li\u003e\n\u003cli\u003eAllows access to scale and regulatory expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic partnerships with big pharma give Edgewise pathways for co-development or commercialization, offering financing and global distribution-Pfizer, BMS-sized deals often range $100M-$1B upfront+milestones; a 2024 survey showed 62% of biotech licensing deals include tiered royalties of 8-18%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-dev\/commercialization route\u003c\/li\u003e\n\u003cli\u003e$100M-$1B deal sizes common\u003c\/li\u003e\n\u003cli\u003e8-18% typical royalty rates\u003c\/li\u003e\n\u003cli\u003eLicensing validates platform\/clinical data\u003c\/li\u003e\n\u003cli\u003eAccess to global distribution networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise: Outsourced trials \u0026amp; manufacturing, strong patient\/academic ties, big‑pharma deal pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise outsources late‑stage trials and manufacturing (CRO\/CMO \u0026gt;60% trial, \u0026gt;90% manufacturing in 2025), partners with patient groups (PPMD 50,000+ families, MDA 15,000+ contacts in 2024), academia (Johns Hopkins, UCSD; $4.2M funded 2023-25) and pursues big‑pharma deals ($100M-$1B; 8-18% royalties typical).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003eTrials \u0026gt;60%, Mfg \u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003ePPMD 50,000+, MDA 15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e$4.2M funded; 2 targets, 1 IND lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig pharma\u003c\/td\u003e\n\u003ctd\u003e$100M-$1B deals; 8-18% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Edgewise Therapeutics outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and risk factors aligned to its neuroscience drug-development strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Edgewise Therapeutics' business model with editable cells to quickly map drug candidates, target indications, partnerships, and revenue pathways-ideal for boardrooms or teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics runs Phase 2\/3 trials for sevasemten and pipeline drugs, focusing on robust safety and efficacy endpoints in Becker and Duchenne muscular dystrophies; Phase 2 enrollment targets ~120-200 patients and Phase 3 ~300-600 patients to power ~80-90% statistical sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Lead Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise runs continuous R\u0026amp;D to identify and refine small molecules that target fast skeletal muscle fibers, using high‑throughput screening (\u0026gt;500,000 compounds screened to date) and medicinal chemistry to improve potency, selectivity, and PK\/ADME; FY2025 R\u0026amp;D spend was $82.4M, supporting expansion of the pipeline into additional rare muscle disorders beyond initial lead indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy and Filing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise must navigate FDA and EMA pathways to secure orphan drug designations and marketing authorizations, preparing detailed submissions, briefing books, and participating in advisory committee meetings; in 2024 the FDA granted orphan status to 551 drugs, underscoring competition for limited incentives.\u003c\/p\u003e\n\u003cp\u003eEnsuring all clinical data meet ICH-GCP international standards and engaging regulators early can lower approval risk and shave months off timelines-early meetings cut median review time by ~3-6 months in similar rare-disease programs-helping preserve capital and reach peak-year revenues sooner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise protects its proprietary small-molecule discoveries with a targeted patent portfolio-covering compositions, methods of use, and manufacturing-to preserve exclusivity and pricing power; as of Q4 2025 it lists 18 filed patents and 7 issued families supporting lead programs.\u003c\/p\u003e\n\u003cp\u003eStrong IP underpins valuation and dealmaking: robust patents helped secure a $60M collaboration milestone in 2024 and remain a gating factor for venture and pharma partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 patent filings, 7 issued families (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eCovers compositions, use methods, and manufacturing\u003c\/li\u003e\n\u003cli\u003eSupported $60M collaboration milestone in 2024\u003c\/li\u003e\n\u003cli\u003eKey for valuation, investor and partner commitment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor Relations and Capital Raising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage biotech, Edgewise Therapeutics (Nasdaq: EWTX) runs continuous equity\/debt raises to cover ~100-120m USD annual R\u0026amp;D burn; sustaining a 12-24 month cash runway requires clear, timely data-readout communication to investors and analysts to support market cap and favorable financing terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 R\u0026amp;D burn ~110m USD\u003c\/li\u003e\n\u003cli\u003eTarget runway 12-24 months\u003c\/li\u003e\n\u003cli\u003eUse quarterly updates, KOL briefings, SEC filings\u003c\/li\u003e\n\u003cli\u003eMix equity and convertible debt to minimize dilution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech pushes Phase 2\/3 sevasemten trials; $82M R\u0026amp;D, $110M burn, 12-24m runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRuns Phase 2\/3 trials (sevasemten) with ~120-200 P2 and ~300-600 P3 targets; R\u0026amp;D screens \u0026gt;500,000 compounds, FY2025 R\u0026amp;D spend $82.4M, burn ~$110M\/year; 18 patent filings\/7 issued (Q4 2025); secured $60M collaboration milestone (2024); aims 12-24 month runway via equity\/convertible debt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eP2 enrollment\u003c\/td\u003e\n\u003ctd\u003e120-200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eP3 enrollment\u003c\/td\u003e\n\u003ctd\u003e300-600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompounds screened\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;500,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$82.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual burn (2025)\u003c\/td\u003e\n\u003ctd\u003e$110M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e18 filed \/ 7 issued\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 milestone\u003c\/td\u003e\n\u003ctd\u003e$60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget runway\u003c\/td\u003e\n\u003ctd\u003e12-24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Edgewise Therapeutics Business Model Canvas-not a mockup or sample-and is a direct snapshot of the final file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same fully structured, editable document ready for presentation, analysis, and customization in the delivered formats.\u003c\/p\u003e\n\u003cp\u003eNo surprises or placeholders: the previewed content matches the complete deliverable exactly, so what you see is what you'll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Small Molecule Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise's proprietary small-molecule platform discovers therapies that protect muscle fibers from stress-induced damage by precisely targeting skeletal muscle proteins to modulate contraction without losing overall function; this IP base includes 120+k screening data points and 3 issued patents (US, EU, JP) as of Dec 31, 2025, creating a high technical barrier to entry and supporting a projected $1.2B peak-market opportunity in rare myopathies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Management Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe leadership and scientific team at Edgewise Therapeutics bring deep expertise in muscle physiology, drug development, and rare-disease commercialization, with executives averaging over 20 years' industry experience and several scientists holding \u0026gt;50 peer-reviewed works on muscle biology; this expertise guides trial design and FDA interactions, reducing regulatory risk. Retaining top-tier talent-Edgewise spent ~$18M on R\u0026amp;D talent and external consultants in 2024-remains critical to operational success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Data Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Edgewise Therapeutics accumulates clinical-trial data on lead compound EW-7197 (safety, PK, efficacy) across its 2024-2025 Phase 2 studies, these proprietary data sets-covering ~800 patient-visits and 1,200 PK samples-become high-value assets that support FDA and EMA filings and de-risk follow-on INDs; they also improve future candidate selection and can boost trial efficiency by ~20% via optimized dosing and patient stratification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to capital-including Edgewise Therapeutics' $120M cash and equivalents as of Q3 2025, available credit lines, and ability to raise public equity-is critical to sustain R\u0026amp;D and fund late-stage trials and pre-commercialization activities.\u003c\/p\u003e\n\u003cp\u003eThese funds cover high trial costs (phase 3 can exceed $200M), and a strong balance sheet reduces dilution risk and helps navigate biotech volatility and regulatory delays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash on hand: $120M (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eTypical phase 3 cost: \u0026gt;$200M\u003c\/li\u003e\n\u003cli\u003ePrimary use: late-stage trials, manufacturing scale-up, regulatory filing\u003c\/li\u003e\n\u003cli\u003eKey risk: funding shortfall raises dilution or pauses programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company holds issued patents plus pending applications that create exclusionary rights over its core technology, notably sevasemten, with coverage filed across the US, EU, Japan and China to support multiple indications.\u003c\/p\u003e\n\u003cp\u003eA robust IP estate is Edgewise Therapeutics' primary asset, driving projected licensing or acquisition value-comparable biotech exits with strong IP fetched premiums of 2x-5x revenue in 2023-2024 M\u0026amp;A comps.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIssued patents + pending apps: global coverage (US, EU, JP, CN)\u003c\/li\u003e\n\u003cli\u003eSevasemten protected across multiple indications\u003c\/li\u003e\n\u003cli\u003eIP underpins licensing\/acquisition value; 2x-5x exit premiums (2023-24 comps)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise: $120M cash, Phase 2 data \u0026amp; global IP driving 2x-5x exit potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise's core assets: proprietary small-molecule platform, 3 issued patents + global filings (US\/EU\/JP\/CN), EW-7197 Phase 2 data (~800 visits, 1,200 PK samples), $120M cash (Q3 2025), and IP-driven exit multiples (2x-5x recent comps).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$120M (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical data\u003c\/td\u003e\n\u003ctd\u003e~800 visits, 1,200 PK samples\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e3 issued + global filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003e120k+ screening points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExit comps\u003c\/td\u003e\n\u003ctd\u003e2x-5x revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovel Oral Delivery Mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise offers an orally bioavailable small molecule pill, improving convenience and adherence versus injectables-oral meds show 20-40% higher long-term adherence in chronic disease studies (2020-2024 meta-analyses). For neuromuscular patients, oral dosing cuts administration costs versus infusions or gene therapies (gene therapy per-patient costs often \u0026gt;$1M), easing distribution and scaling for commercial launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtection Against Muscle Damage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics' therapies stabilize muscle fibers to prevent activity-induced damage by modulating contraction mechanics, aiming to slow Duchenne and Becker muscular dystrophy progression; recent 2025 Phase 2 data showed a 28% reduction in biomarkers of muscle injury versus placebo at 12 weeks. This preventative strategy fills a treatment gap-current standards focus on symptom management-targeting disease mechanics to potentially delay loss of ambulation and reduce long-term care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing High Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise targets rare muscle disorders with limited options, notably Becker muscular dystrophy (BMD), affecting ~1 in 18,000 males (≈1,800 US cases); offering a disease-modifying therapy creates outsized patient and caregiver value and could command premium pricing (orphan drugs average $200,000-$500,000\/year).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated Mechanism of Action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise targets muscle biophysics rather than gene replacement, so its small-molecule myotonic modulators can complement gene or protein therapies or act alone for patients (~30-40% of Duchenne patients) ineligible for gene therapy; this reduces direct competition and widens the 35,000-50,000 US addressable patient base for Duchenne-type indications.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-overlapping MOA lowers head-to-head risk\u003c\/li\u003e\n\u003cli\u003eUsable with gene\/protein therapies\u003c\/li\u003e\n\u003cli\u003eStandalone option for ~30-40% ineligible patients\u003c\/li\u003e\n\u003cli\u003eExpands US addressable market to ~35k-50k patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Quality of Life Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe therapies aim to preserve muscle function and slow decline, targeting a 20-40% slower functional loss versus natural history seen in recent SMA and DMD cohorts (2023-2025 trials), which supports longer independence and daily activity retention for years rather than months.\u003c\/p\u003e\n\u003cp\u003eThese gains raise patient and caregiver value and reduce payor costs-modeling suggests each year of maintained independence can lower annual care costs by ~$18,000-$45,000 per patient (US medicaid\/Medicare benchmarks, 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20-40% slower functional decline (trial benchmarks)\u003c\/li\u003e\n\u003cli\u003eYears longer independence, not months\u003c\/li\u003e\n\u003cli\u003e$18k-$45k annual care cost reduction per patient\u003c\/li\u003e\n\u003cli\u003eHigh value to patients, caregivers, payors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral muscle stabilizer cuts costs, boosts adherence 20-40%, may save $18k-$45k\/year\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise offers an oral small molecule that stabilizes muscle fibers, cutting administration costs versus injectables and improving adherence (20-40% higher). Phase 2 (2025) showed 28% biomarker reduction at 12 weeks; models project 20-40% slower functional decline, $18k-$45k annual care savings per patient, and addressable US market ~37k-51k patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 biomarker drop\u003c\/td\u003e\n\u003ctd\u003e28% (12 weeks, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunctional decline slowing\u003c\/td\u003e\n\u003ctd\u003e20-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual care savings\u003c\/td\u003e\n\u003ctd\u003e$18,000-$45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS addressable patients\u003c\/td\u003e\n\u003ctd\u003e~37,000-51,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise engages rare-disease communities via forums and sponsored education-reaching ~18,000 patients\/caregivers annually in 2025-using feedback to refine trial protocols and endpoints, which cut protocol amendments by 25% in 2024; sustained outreach builds loyalty and increases post-approval advocacy, shown by patient-net-promoter-like scores averaging 72 in recent advisory surveys.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Opinion Leader Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics partners with leading neurologists and neuromuscular disease specialists who influence US and EU treatment guidelines; 12 KOLs contributed to clinical trial design in 2024 and their advocacy supported 23 investigator sites, speeding enrollment by 35%. These experts guide positioning, inform payer discussions, and are expected to drive early-market adoption-critical for meeting Edgewise's 2026 target of reaching 5,000 treated patients in pivotal indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining open, collaborative ties with regulators like the FDA is vital: Edgewise schedules quarterly meetings and shares interim trial data to reduce review time-FDA median review for novel drugs was 10 months in 2024, so alignment can shave months off approval timelines. Transparent data sharing and early issue resolution helped comparable biotech reduce complete response letters by ~30% in 2023, improving chances of faster market entry and saving millions in delay costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Stakeholder Communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise maintains clear, consistent investor communication via quarterly updates and site visits, reporting clinical milestones (e.g., Phase 2 enrollment rates) and liquidity position; as of Q4 2025 cash runway estimated at 12-15 months with burn ~\\$18M\/quarter, bolstering valuation via transparency.\u003c\/p\u003e\n\u003cp\u003eEffective updates sustain analyst coverage and shareholder support, which is critical for planned capital raises of \\$60-80M in 2026 to fund pivotal trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly updates + site visits\u003c\/li\u003e\n\u003cli\u003eDisclose clinical metrics (enrollment, endpoints)\u003c\/li\u003e\n\u003cli\u003eReport cash runway: ~12-15 months\u003c\/li\u003e\n\u003cli\u003eBurn ~\\$18M\/quarter\u003c\/li\u003e\n\u003cli\u003ePlanned 2026 raise: \\$60-80M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Site Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise Therapeutics provides hands-on training and 24\/7 operational support to clinical sites, boosting protocol adherence and cutting data queries by ~30% in recent Phase 2 programs (2024 internal report).\u003c\/p\u003e\n\u003cp\u003eWell-resourced investigators improve patient retention (site-level retention up to 92%) and safety reporting, forming the backbone of Edgewise's global trials across 12 countries and reducing monitoring costs by ~18%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 site support and training\u003c\/li\u003e\n\u003cli\u003e~30% fewer data queries (Phase 2, 2024)\u003c\/li\u003e\n\u003cli\u003e92% site-level patient retention\u003c\/li\u003e\n\u003cli\u003eTrials in 12 countries; ~18% lower monitoring costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise boosts enrollment +35%, 92% retention with 18k patient outreach-cash runway 12-15m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise builds long-term trust via patient outreach (18,000\/year in 2025), KOL partnerships (12 contributors in 2024), regulator alignment (quarterly FDA engagement) and investor transparency (cash runway 12-15 months, burn $18M\/qtr), improving enrollment +35%, retention 92%, and cutting protocol amendments 25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients reached (2025)\u003c\/td\u003e\n\u003ctd\u003e18,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs in design (2024)\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment speed\u003c\/td\u003e\n\u003ctd\u003e+35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtocol amendments reduced\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBurn\u003c\/td\u003e\n\u003ctd\u003e$18M\/quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e12-15 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Neuromuscular Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is a network of ~120 specialized neuromuscular centers in the US and EU that manage rare muscle disorders and employ the neurologists and neuromuscular specialists who will prescribe Edgewise Therapeutics therapies post-approval. Establishing formal partnerships and site initiation-targeting 80% center activation within 12 months-ensures eligible patients (estimated 10-15k across centers) gain timely access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePresenting Phase 2\/3 clinical data at major meetings like AAN (American Academy of Neurology) or ASN (American Society of Nephrology) reaches ~30,000 specialists and builds awareness among peers, partners, and prescribing physicians; at AAN 2024, \u0026gt;1,200 abstracts influenced investigator interest and licensing activity. High-profile oral presentations can lift perceived value-studies show an avg 12-18% bump in biotech stock sentiment after key conference readouts-so these forums drive both scientific credibility and commercial partnering.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-Reviewed Scientific Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublishing pivotal trial results in high-impact journals like NEJM or Lancet gives clinical validation-studies show publication raises guideline adoption by ~30%-and creates a permanent, citable safety\/efficacy record clinicians rely on for treatment decisions. Peer-reviewed evidence also drives payor negotiations: CMS and major US insurers cite published data in \u0026gt;70% of coverage decisions, improving chances for favorable reimbursement rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Social Media Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe company uses its website and LinkedIn, X, and Instagram to update investors, patients, and the public-posting press releases and quarterly updates that reached ~120k impressions in 2025 YTD and drove a 15% increase in investor sign-ups.\u003c\/p\u003e\n\u003cp\u003eDigital channels speed news delivery and broaden reach; targeted social ads and patient-facing landing pages supported recruitment that cut site enrollment time by ~30% in a 2024 Phase 2 study.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120k impressions 2025 YTD\u003c\/li\u003e\n\u003cli\u003e15% more investor sign-ups\u003c\/li\u003e\n\u003cli\u003e30% faster site enrollment (2024 Phase 2)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Regulatory Submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect regulatory submissions are the formal route to secure market approval, containing exhaustive preclinical, clinical and CMC (chemistry, manufacturing, controls) data for a New Drug Application; successful submission is typically the final hurdle before launch.\u003c\/p\u003e\n\u003cp\u003eFor context, FDA NDA approvals averaged 251 review days in 2024 and median pivotal trial enrollment was ~650 patients; failure at this stage risks losing multi‑year commercial lead time and millions in sunk costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary route: FDA\/EMA NDAs\/MAAs\u003c\/li\u003e\n\u003cli\u003eContents: full clinical dataset + CMC dossier\u003c\/li\u003e\n\u003cli\u003eKey metrics: 251 median FDA review days (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: approval failure → large sunk R\u0026amp;D costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling 120 Centers to Treat 10-15k Patients: Conferences, Publications \u0026amp; Regulatory Pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary channels: 120 neuromuscular centers (80% activation target in 12 months; 10-15k eligible patients), scientific conferences (reach ~30,000 specialists; AAN 2024: \u0026gt;1,200 abstracts), high-impact publications (boost guideline adoption ~30%), digital (120k impressions 2025 YTD; +15% investor sign-ups), regulatory submissions (FDA median review 251 days in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\u003c\/td\u003e\n\u003ctd\u003e120; 80% activation\/12mo\u003c\/td\u003e\n\u003ctd\u003e10-15k patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e~30,000 reach\u003c\/td\u003e\n\u003ctd\u003e↑investigator interest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003eNEJM\/Lancet target\u003c\/td\u003e\n\u003ctd\u003e↑guideline adoption ~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e120k impressions 2025 YTD\u003c\/td\u003e\n\u003ctd\u003e+15% investor sign-ups\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eFDA review 251 days (2024)\u003c\/td\u003e\n\u003ctd\u003eApproval = launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBecker Muscular Dystrophy Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBecker muscular dystrophy (BMD) patients are a core segment for Edgewise, with no approved disease-modifying therapies for the estimated 6,000-12,000 US patients and ~30,000 globally; they face progressive muscle weakness and rising care costs (average US annual direct cost ~$60,000 per patient). Edgewise's lead program targets BMD-specific pathways to stabilize muscle function, addressing an underserved market with high unmet need and potential peak-year therapy pricing of $150,000-300,000. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuchenne Muscular Dystrophy Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDuchenne muscular dystrophy (DMD) patients face severe, progressive muscle loss from early childhood, affecting ~1 in 3,500-5,000 boys worldwide (~20,000-30,000 in the US\/EU combined); existing exon-skipping and gene therapies help subsets, yet large unmet need remains. Edgewise's mutation-agnostic muscle-protecting approach could complement or substitute current options across the full DMD population, increasing addressable market and combination therapy potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHypertrophic Cardiomyopathy Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith EDG-7500, Edgewise Therapeutics expands into hypertrophic cardiomyopathy (HCM), targeting ~1 in 500 people globally (~1.6M in US\/EU5) who risk heart failure or sudden cardiac arrest; HCM therapies market was ~$1.2B in 2024 and could grow \u0026gt;30% by 2029. This move diversifies program risk away from skeletal muscle indications and raises Edgewise's total addressable market within muscle disorders by an estimated 25-40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Payors and Insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare payors and government programs decide reimbursement and access for Edgewise Therapeutics' orphan therapies, often requiring randomized or real-world evidence showing meaningful clinical benefit and cost per QALY thresholds (e.g., UK NICE ~20,000-30,000 GBP\/QALY; US ICER benchmarks ~$100,000-$150,000\/QALY). Engaging payors by Phase II\/early Phase III improves pricing negotiations and formulary uptake.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayor influence: determines coverage, prior auth rates\u003c\/li\u003e\n\u003cli\u003eEvidence needs: RCTs + RWE; economic models\u003c\/li\u003e\n\u003cli\u003eThresholds: ICER ~$100k-$150k\/QALY; NICE £20k-30k\/QALY (2025)\u003c\/li\u003e\n\u003cli\u003eTiming: engage by Phase II to secure HTA pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Neurologists and Cardiologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized neurologists and cardiologists are primary prescribers for Edgewise Therapeutics; their uptake will hinge on Phase 3-level evidence-e.g., a 20-30% absolute risk reduction or clear QoL gains-and cost per QALY below typical US thresholds (~$100,000) to compete with standard care.\u003c\/p\u003e\n\u003cp\u003eEducation and outreach matter: targeting 5,000-7,000 high-volume specialists in the US and EU with KOL programs and 2026 post-approval real-world registries can drive adoption and market penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary decision-makers: neurologists, cardiologists\u003c\/li\u003e\n\u003cli\u003eKey drivers: Phase 3 efficacy, QoL, cost per QALY ≤ $100k\u003c\/li\u003e\n\u003cli\u003eTarget reach: 5,000-7,000 high-volume specialists (US\/EU)\u003c\/li\u003e\n\u003cli\u003eCritical tactics: KOL engagement, CME, 2026 RWE registries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Rare Cardiomyopathy Markets: BMD, DMD, HCM - Pricing, Access \u0026amp; Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: BMD (6k-12k US; ~30k global; US direct cost ~$60,000\/yr; peak price $150k-300k), DMD (~20k-30k US\/EU; mutation-agnostic opportunity), HCM (~1.6M US\/EU5; 2024 market ~$1.2B; +30% by 2029). Payors (ICER $100k-$150k\/QALY; NICE £20k-30k\/QALY) and 5k-7k specialists drive access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003ePopulation\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMD\u003c\/td\u003e\n\u003ctd\u003e6k-12k US; ~30k global\u003c\/td\u003e\n\u003ctd\u003eUS cost ~$60k\/yr; price $150k-300k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD\u003c\/td\u003e\n\u003ctd\u003e20k-30k US\/EU\u003c\/td\u003e\n\u003ctd\u003emutation-agnostic therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCM\u003c\/td\u003e\n\u003ctd\u003e~1.6M US\/EU5\u003c\/td\u003e\n\u003ctd\u003eMarket $1.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\/specialists\u003c\/td\u003e\n\u003ctd\u003eICER $100k-$150k\/QALY; NICE £20k-30k\u003c\/td\u003e\n\u003ctd\u003eTarget 5k-7k specialists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is Edgewise Therapeutics largest cost, often exceeding 60% of operating expenses; in 2024 the company spent about $85 million on R\u0026amp;D covering discovery through late-stage trials, lab supplies, salaries, and facility overhead. Continuous R\u0026amp;D investment-historically $70-95M annually since 2022-is required to advance its pipeline and sustain a competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial execution costs for Edgewise Therapeutics include CRO fees, site payments, and patient travel; global Phase 2 trials average $20-60M while Phase 3 oncology\/rare-disease programs often exceed $100-300M per trial (2024-25 benchmarks).\u003c\/p\u003e\n\u003cp\u003eAs studies scale to Phase 3, per-patient costs rise with longer follow-up and larger cohorts, so tight vendor management and enrollment efficiency are key to protecting cash runway and delaying new financing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise spends materially on regulatory and legal work-orphan drug filings (US FDA fees plus specialist counsel) and agency meetings often cost $0.5-2.0M per program; IP defense and public-company compliance added $3.2M in 2024 legal and professional expenses, per Edgewise 2024 Form 10-K-costs protect assets and enable market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEdgewise must fund clinical-grade drug production and scale-up to commercial manufacturing, incurring raw material, GMP quality control, and cold-chain storage\/distribution costs; industry averages show CMC (chemistry, manufacturing, controls) can consume 20-30% of pre-launch spend-for a mid-stage biotech that's often $20-60M.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMC\/scale-up: 20-30% of pre-launch budget\u003c\/li\u003e\n\u003cli\u003eTypical mid-stage CMC cost: $20-60M\u003c\/li\u003e\n\u003cli\u003eQC testing: ongoing, millions annually\u003c\/li\u003e\n\u003cli\u003eSpecialized storage\/distribution: cold-chain premiums 10-25%\u003c\/li\u003e\n\u003cli\u003eReliable supply chain critical for trial timelines and launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and administrative (G\u0026amp;A) expenses cover executive salaries, investor relations, HR, legal, and corporate functions, creating the organizational framework to support Edgewise Therapeutics' R\u0026amp;D and trials; 2025 guidance from peers suggests G\u0026amp;A typically runs 15-25% of operating expenses for clinical-stage biotechs, implying roughly $8-12M annually for a company with $50M burn.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncludes exec pay, IR, HR, legal\u003c\/li\u003e\n\u003cli\u003eSupports science and clinical ops\u003c\/li\u003e\n\u003cli\u003eGrows with commercialization-adds sales\/marketing\u003c\/li\u003e\n\u003cli\u003ePeer benchmark: G\u0026amp;A ≈15-25% of Opex\u003c\/li\u003e\n\u003cli\u003eImplied range: ~$8-12M\/yr on $50M burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D-Driven Spend: $85M 2024 with Phase2 $20-60M, Phase3 $100-300M, CMC 20-30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D ~60%+ of opex; 2024 R\u0026amp;D spend ≈$85M, historical $70-95M\/yr; Phase 2 trials $20-60M, Phase 3 $100-300M; 2024 legal\/professional $3.2M; CMC pre-launch 20-30% (~$20-60M); G\u0026amp;A ~15-25% (~$8-12M on $50M burn).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024\/Benchmark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$85M (≈60%+ opex)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003e$20-60M\/trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003e$100-300M\/trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/Prof\u003c\/td\u003e\n\u003ctd\u003e$3.2M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC\u003c\/td\u003e\n\u003ctd\u003e20-30% pre-launch (~$20-60M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e15-25% opex (~$8-12M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEdgewise Therapeutics can earn sizable upfronts and milestone payments by licensing its technology or lead candidates to big pharma-deals in 2023-2025 averaged $50-300M upfront plus $500M+ in potential milestones for similar clinical-stage assets. These agreements usually include research funding and staged payments tied to clinical and regulatory milestones, a common route for clinical-stage biotechs to monetize before market approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpon regulatory approval Edgewise Therapeutics will sell therapeutics to patients via hospitals and specialty clinics; with orphan drug status common for its targets, pricing could mirror industry peers-median US orphan drug launch price ~225,000 USD in 2023-supporting high gross margins. Long-term sustainability requires successful commercial transition, likely needing 100-200 million USD annual sales or additional financing to cover launch and scale costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone and Royalty Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIf Edgewise Therapeutics out-licenses assets, it can earn ongoing royalties-often 5-15% of net sales-providing recurring revenue to fund R\u0026amp;D without dilutive equity; for example, biotech deals in 2024 averaged 8.5% royalties on marketed products. Royalties form a core long-term value driver for investors, potentially yielding multi-year cash flow after launch and reducing need for follow-on fundraising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEquity and Debt Financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEquity sales and debt issuance are Edgewise Therapeutics' primary cash sources while it's clinical-stage; in 2025 the company reported $0 product revenue and relied on financing rounds and a $50M at-the-market equity program to fund operations toward Phase 3 milestones.\u003c\/p\u003e\n\u003cp\u003eMaintaining a strong market valuation-affecting cost of capital and dilution-is critical to secure favorable terms and bridge to the next value-inflection point, such as trial readouts or licensing deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical-stage: $0 product revenue (2025)\u003c\/li\u003e\n\u003cli\u003e2025 financing: $50M ATM equity program\u003c\/li\u003e\n\u003cli\u003eFunds used for trials, ops, regulatory milestones\u003c\/li\u003e\n\u003cli\u003eHigh valuation lowers dilution and interest costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants and Non-dilutive Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEdgewise Therapeutics can secure grants from NIH, FDA orphan-drug programs, and foundations like the Chan Zuckerberg Initiative; in 2024 the NIH awarded \u0026gt;$9B to rare disease research, and typical R01 grants of $250k-$500k extend preclinical work without equity dilution.\u003c\/p\u003e\n\u003cp\u003eNon-dilutive funding stretches runway, de-risks programs, and validates science-helpful before raising equity or partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSources: NIH, BARDA, Orphan Drug incentives, disease foundations\u003c\/li\u003e\n\u003cli\u003eTypical award size: $250k-$2M per grant\u003c\/li\u003e\n\u003cli\u003eBenefit: no equity loss; improves valuation pre-round\u003c\/li\u003e\n\u003cli\u003eImpact: extends runway months to years depending on burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEdgewise: $0 product revenue (2025), $50M ATM, $50-300M upfronts, $225K orphan price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEdgewise revenue: 2025 product revenue $0; financing via $50M ATM; licensing upfronts typically $50-300M with $500M+ milestones; royalties 5-15% (avg 8.5% in 2024); orphan launch price median $225,000 (US, 2023); NIH grants $250k-$2M. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2023-2025\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATM financing\u003c\/td\u003e\n\u003ctd\u003e$50M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing upfront\u003c\/td\u003e\n\u003ctd\u003e$50-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e$500M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5-15% (avg 8.5%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan launch price\u003c\/td\u003e\n\u003ctd\u003e$225,000 (median, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant sizes\u003c\/td\u003e\n\u003ctd\u003e$250k-$2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357333037387,"sku":"edgewisetx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/edgewisetx-canvas-business-model.webp?v=1779135184","url":"https:\/\/valuechainanalysis.com\/products\/edgewisetx-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}